滚动资讯
CellRational discovery of therapeutic PAK1 allosteric activatorsCellA 3D morphogenetic blueprint for metastatic outgrowth in breast cancerCellArbitrium phages can manipulate each other’s lysis/lysogeny decisionsCellSulfur partitioning from cysteine controls T cell proliferation and effector functionCellPhages communicate across species to shape microbial ecosystemsFierceBiotechFDA extends review of Orca Bio’s novel cell therapy for blood cancersFierceBiotech‘There isn't as much meat left to cut’: Biopharma layoffs maintain slowdown in Q1FierceBiotechOric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock downFierceBiotechAlzheimer's-focused Korsana to use Cyclerion reverse merger to go publicEndpoints NewsLilly wins approval of anti-obesity pill orforglipron, setting up new battle with NovoEndpoints NewsAmgen, Zai Lab team up on DLL3; Janux gets $35M milestone paymentEndpoints NewsParagon offshoot Korsana to go public in reverse merger for Alzheimer's work
FierceBiotech 2026年4月1日

FDA extends review of Orca Bio’s novel cell therapy for blood cancers

FDA extends review of Orca Bio’s novel cell therapy for blood cancers

原文
暂时没有全文，请查看原始来源。

目录

59 全部